Adjuvant Docetaxel for Node-Positive Breast Cancer

To the Editor: The study by Martin et al. (June 2 issue) 1 raises concern about the high rates of febrile neutropenia among patients receiving a regimen of docetaxel plus doxorubicin and cyclophosphamide (TAC). Moreover, it is not clear that the right comparator is a regimen of fluorouracil plus doxorubicin and cyclophosphamide (FAC). Dose-dense regimens have been shown to be effective and less toxic. 2 A recent study was prematurely terminated because of an unacceptable rate of life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel. 3 We think that docetaxel-based adjuvant chemotherapy cannot be advocated as a standard approach in the management of . . .